Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib versus chemotherapy for recurrent clear cell carcinoma of the ovary or endometrium
2013-002109-73Phase 2Completed
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nintedanib in clear cell ovarian cancer and clear cell endometrial carcinoma (CCEC) (2 arms), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Progression-free survival. Started Dec 2013; status: completed.
02
Drugs
nintedanib
03
Conditions
clear cell ovarian cancerclear cell endometrial carcinoma (CCEC)
Beyond the preview
Go deeper on 2013-002109-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002109-73.